Efficacy of Omentum-Preserving Gastrectomy for Patients With Gastric Cancer: A Systematic Review and Meta-Analysis.
gastric cancer
omentectomy
omentum-preserving gastrectomy
oncological outcomes
surgical outcomes
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2021
2021
Historique:
received:
17
05
2021
accepted:
18
08
2021
entrez:
20
9
2021
pubmed:
21
9
2021
medline:
21
9
2021
Statut:
epublish
Résumé
Complete omentectomy is considered to be essential in the radical gastrectomy for gastric cancer (GC), but its clinical benefit remains unclear. This study aims to evaluate the efficacy of omentum-preserving gastrectomy (OPG) for patients with GC. Studies comparing the surgical and oncological outcomes of OPG and gastrectomy with complete omentectomy (GCO) for GC up to March 2021 were systematically searched from PubMed, Web of Science, Embase, and Cochrane Library. A pooled analysis was performed for the available data regarding the baseline features, surgical and oncological outcomes. The RevMan 5.3 software was used to perform the statistical analysis. Quality evaluation and publication bias were also conducted. Nine studies with a total of 3335 patients (1372 in the OPG group and 1963 in the GCO group) undergoing gastrectomy were included. In the pooled analysis, the baseline data in two groups were all comparable (p > 0.05). However, the OPG group was associated with shorter operative time (MD = -18.67, 95% CI = -31.42 to -5.91, P = 0.004) and less intraoperative blood loss (MD = -38.09, 95% CI = -53.78 to -22.41, P < 0.00001) than the GCO group. However, the number of dissected lymph nodes (MD = 2.16, 95% CI = -0.61 to 4.93, P = 0.13), postoperative complications (OR = 0.92, 95% CI = 0.74 to 1.15, p = 0.47), overall recurrence rate (OR = 0.83, 95% CI = 0.66 to 1.06, p = 0.14), peritoneal recurrence rate (OR = 0.91, 95% CI = 0.65 to 1.29, p = 0.60), 3-year relapse-free survival (RFS) rate (OR = 1.40, 95% CI = 0.86 to 2.27, p = 0.18), and 5-year RFS rate (OR = 1.21, 95% CI = 0.95 to 1.55, p = 0.12) of the two groups were comparable. OPG might be an oncologically safe procedure with better surgical outcomes for patients with GC than GCO. However, high-quality randomized controlled trials are needed to confirm this benefit.
Sections du résumé
BACKGROUND
BACKGROUND
Complete omentectomy is considered to be essential in the radical gastrectomy for gastric cancer (GC), but its clinical benefit remains unclear. This study aims to evaluate the efficacy of omentum-preserving gastrectomy (OPG) for patients with GC.
METHODS
METHODS
Studies comparing the surgical and oncological outcomes of OPG and gastrectomy with complete omentectomy (GCO) for GC up to March 2021 were systematically searched from PubMed, Web of Science, Embase, and Cochrane Library. A pooled analysis was performed for the available data regarding the baseline features, surgical and oncological outcomes. The RevMan 5.3 software was used to perform the statistical analysis. Quality evaluation and publication bias were also conducted.
RESULTS
RESULTS
Nine studies with a total of 3335 patients (1372 in the OPG group and 1963 in the GCO group) undergoing gastrectomy were included. In the pooled analysis, the baseline data in two groups were all comparable (p > 0.05). However, the OPG group was associated with shorter operative time (MD = -18.67, 95% CI = -31.42 to -5.91, P = 0.004) and less intraoperative blood loss (MD = -38.09, 95% CI = -53.78 to -22.41, P < 0.00001) than the GCO group. However, the number of dissected lymph nodes (MD = 2.16, 95% CI = -0.61 to 4.93, P = 0.13), postoperative complications (OR = 0.92, 95% CI = 0.74 to 1.15, p = 0.47), overall recurrence rate (OR = 0.83, 95% CI = 0.66 to 1.06, p = 0.14), peritoneal recurrence rate (OR = 0.91, 95% CI = 0.65 to 1.29, p = 0.60), 3-year relapse-free survival (RFS) rate (OR = 1.40, 95% CI = 0.86 to 2.27, p = 0.18), and 5-year RFS rate (OR = 1.21, 95% CI = 0.95 to 1.55, p = 0.12) of the two groups were comparable.
CONCLUSIONS
CONCLUSIONS
OPG might be an oncologically safe procedure with better surgical outcomes for patients with GC than GCO. However, high-quality randomized controlled trials are needed to confirm this benefit.
Identifiants
pubmed: 34540677
doi: 10.3389/fonc.2021.710814
pmc: PMC8447879
doi:
Types de publication
Systematic Review
Langues
eng
Pagination
710814Informations de copyright
Copyright © 2021 Li, Song, Zhou, Jiang, Xu, Hu, Liu, Jiang and Li.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Gastrointest Surg. 2020 Dec;24(12):2856-2858
pubmed: 32789594
Surg Endosc. 2019 Jan;33(1):33-45
pubmed: 30386984
Lancet Gastroenterol Hepatol. 2018 Jul;3(7):460-468
pubmed: 29709558
Gastric Cancer. 2021 Jan;24(1):1-21
pubmed: 32060757
Surgery. 2021 Aug;170(2):610-616
pubmed: 33714618
World J Surg. 2021 Jun;45(6):1803-1811
pubmed: 33566122
Br J Cancer. 2020 Aug;123(3):459-470
pubmed: 32439934
BMC Med Res Methodol. 2005 Apr 20;5:13
pubmed: 15840177
Gastric Cancer. 2012 Jan;15(1):42-8
pubmed: 21573917
Jpn J Clin Oncol. 2020 Oct 22;50(11):1321-1324
pubmed: 32638017
Br J Surg. 2016 Oct;103(11):1497-503
pubmed: 27550526
World J Surg Oncol. 2014 Mar 26;12:64
pubmed: 24669875
World J Surg. 2008 Aug;32(8):1703-8
pubmed: 18536863
World J Gastroenterol. 2000 Apr;6(2):169-176
pubmed: 11819552
Yonsei Med J. 2011 Nov;52(6):961-6
pubmed: 22028160
Sci Rep. 2020 Oct 1;10(1):16305
pubmed: 33004919
J Laparoendosc Adv Surg Tech A. 2020 Jul;30(7):749-758
pubmed: 32155379
J Clin Oncol. 2020 Oct 1;38(28):3304-3313
pubmed: 32816629
N Engl J Med. 2007 Nov 1;357(18):1810-20
pubmed: 17978289
Gastric Cancer. 2013 Jul;16(3):383-8
pubmed: 22983455
Br J Surg. 2020 Nov;107(12):1640-1647
pubmed: 32430907
BMC Cancer. 2019 Mar 7;19(1):206
pubmed: 30845995